| Autor: |
Consoli, Ugo, Santonocito, AnnaMaria, Stagno, Fabio, Fiumara, Paolo, Privitera, Antonella, Parisi, Giuseppina, Giustolisi, Giada M, Pavone, Biagia, Palumbo, Giuseppe A, Di Raimondo, Francesco, Milone, Giuseppe, Giustolisi, Rosario |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Mar2002, Vol. 116 Issue 4, p774-780, 7p |
| Abstrakt: |
Summary. We evaluated the presence of P-glycoprotein (P-gp)-170, multidrug resistance protein (MRP), lung resistance protein (LRP)-56 and Bcl-2 in CD19-positive cells from 100 cases of chronic lymphocytic leukaemia (CLL). P-gp-170 was found in 73% of the CLL cases with no significant difference regarding stage or previous treatment. LRP-56 protein was homogeneously distributed with no differences for stage or treatment. MRP protein was detected at a low level of expression in 49·4% of CLL patients with no differences for stage or treatment. Bcl-2 protein was expressed at a high level in all CLL patients and higher levels were found in the advanced stage. This leads us to conclude that P-gp, MRP, LRP-56 and Bcl-2 are frequently expressed in CLL. P-gp, MRP and LRP are not correlated to stage or previous treatment. Bcl-2 is higher in advanced-stage patients. The clinical and biological significance of these zMDR mechanisms in CLL remains to be fully explained. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text